PD184352 (CI-1040)

Catalog No.S1020

Molecular Weight(MW): 478.67

PD184352 (CI-1040) is an ATP non-competitive MEK1/2 inhibitor with IC50 of 17 nM in cell-based assays, 100-fold more selective for MEK1/2 than MEK5. Phase 2.

Cited by 62 Publications

Cancer Cell, 2016, 10.1016/j.ccell.2016.01.006

PubMed: 26859455 ( click the link to review the publication )

Cancer Discov, 2013, 3(9):1058-71

PubMed: 23744832 ( click the link to review the publication )

Cancer Discov, 2012, 2(10):934-47

PubMed: 22961667 ( click the link to review the publication )

Science, 2011, 331(6019):912-6

PubMed: 21330545 ( click the link to review the publication )

Nat Genet, 2011, 44(2):133-9

PubMed: 22197931 ( click the link to review the publication )

Mol Cell, 2019, 74(5):1086-1102.e5

PubMed: 31101498 ( click the link to review the publication )

Elife, 2018, 10.7554/eLife.40167

PubMed: 30561326 ( click the link to review the publication )

Sci Rep, 2018, 8(1):18043

PubMed: 30575780 ( click the link to review the publication )

Cancer Res, 2017, 77(5):1212-1226

PubMed: 28087600 ( click the link to review the publication )

J Hematol Oncol, 2017, 10(1):19

PubMed: 28100259 ( click the link to review the publication )

FASEB J, 2017, 31(5):1903-1915

PubMed: 28174207 ( click the link to review the publication )

Antiviral Res, 2017, 142:178-184

PubMed: 28377100 ( click the link to review the publication )

Biochem Pharmacol, 2017, 136:40-50

PubMed: 28404378 ( click the link to review the publication )

Methods Mol Biol, 2017, 1487:163-174

PubMed: 27924566 ( click the link to review the publication )

Elife, 2016, 10.7554/eLife.11414

PubMed: 26999821 ( click the link to review the publication )

Cell Mol Immunol, 2016, 13(5):658-68

PubMed: 26189368 ( click the link to review the publication )

Drug Metab Dispos, 2016, 44(5):665-71

PubMed: 26953171 ( click the link to review the publication )

Oncol Lett, 2016, 11(1):99-104

PubMed: 26870175 ( click the link to review the publication )

Eur Rev Med Pharmacol Sci, 2016, 20(10):1961-8

PubMed: 27249593 ( click the link to review the publication )

Oncogene, 2015, 10.1038/onc.2015.12

PubMed: 25684139 ( click the link to review the publication )

Cell Death Dis, 2015, 6:e1711

PubMed: 25837487 ( click the link to review the publication )

Anim Reprod Sci, 2015, 161:47-57

PubMed: 26307658 ( click the link to review the publication )

Cytometry A, 2015, 10.1002/cyto.a.22628

PubMed: 25598437 ( click the link to review the publication )

eNeuro, 2015, 2(5)

PubMed: 26730399 ( click the link to review the publication )
J Clin Invest, 2014, 124(7):3016-31

PubMed: 24937430 ( click the link to review the publication )

EMBO Mol Med, 2014, 7(1):102-23

PubMed: 25550395 ( click the link to review the publication )

Cancer Lett, 2014, 347(2):212-24

PubMed: 24576622 ( click the link to review the publication )

Cancer Lett, 2014, 348(1-2):38-49

PubMed: 24650799 ( click the link to review the publication )

Cell Death Dis, 2014, 5:e1445

PubMed: 25299770 ( click the link to review the publication )

FASEB J, 2014, 28(10):4551-62

PubMed: 25008089 ( click the link to review the publication )

Mol Cell Proteomics, 2014, 13(6):1429-38

PubMed: 24643969 ( click the link to review the publication )

Biochem J, 2014, 459(3):513-24

PubMed: 24527759 ( click the link to review the publication )

Virology, 2014, 468-470C:490-503

PubMed: 25261871 ( click the link to review the publication )

BMC Cancer, 2014, 14(1):240

PubMed: 24708867 ( click the link to review the publication )

PLoS One, 2014, 9(12):e114389

PubMed: 25486532 ( click the link to review the publication )

Clin Cancer Res, 2013, 19(20):5749-57

PubMed: 23948972 ( click the link to review the publication )

Clin Cancer Res, 2013, 19(20):5749-57

PubMed: 23948972 ( click the link to review the publication )

Cancer Res, 2013, 73(20):6346-58

PubMed: 23966295 ( click the link to review the publication )

Dis Model Mech, 2013, 6(2):521-9

PubMed: 22996645 ( click the link to review the publication )

PLoS One, 2013, 8(10):e76505

PubMed: 24124570 ( click the link to review the publication )

PLoS One, 2013, 8(9):e73548

PubMed: 24019927 ( click the link to review the publication )

PLoS One, 2013, 8(7):e68378

PubMed: 23874604 ( click the link to review the publication )

J Natl Cancer Inst, 2012, 104(21):1673-9

PubMed: 22997239 ( click the link to review the publication )

Oncogene, 2012, 32(38):4480-9

PubMed: 23108403 ( click the link to review the publication )

Breast Cancer Res, 2012, 14(4):R111

PubMed: 22817771 ( click the link to review the publication )

Neoplasia, 2012, 14(4):283-96

PubMed: 22577344 ( click the link to review the publication )

J Biol Chem, 2012, 288(6):4174-93

PubMed: 23255592 ( click the link to review the publication )

J Biol Chem, 2012, 287(33):27863-75

PubMed: 22685289 ( click the link to review the publication )
Mol Endocrinol, 2012, 26(6):1056-73

PubMed: 22570334 ( click the link to review the publication )

Int J Parasitol, 2012, 40(5):555-67

PubMed: 19887070 ( click the link to review the publication )

J Cell Biochem, 2012, 113(1):360-71

PubMed: 21928324 ( click the link to review the publication )

J Biomol Screen, 2012, 17(6):813-21

PubMed: 22453235 ( click the link to review the publication )

J Exp Med, 2011, 208(9):1889-900

PubMed: 21825016 ( click the link to review the publication )

Proc Natl Acad Sci USA, 2011, 108(39):16392-7

PubMed: 21930937 ( click the link to review the publication )

Cell Death Dis, 2011, 2:e124

PubMed: 21368895 ( click the link to review the publication )

Neoplasia, 2011, 13(2):154-66

PubMed: 21403841 ( click the link to review the publication )

Dis Model Mech, 2011, 4(3):393-9

PubMed: 21263000 ( click the link to review the publication )

Antiviral Res, 2011, 92(2):195-203

PubMed: 21854809 ( click the link to review the publication )

Toxicol Sci, 2011, 123(2):542-9

PubMed: 21742783 ( click the link to review the publication )

Front Physiol, 2011, 2:71

PubMed: 22028692 ( click the link to review the publication )

Sci Signal, 2010, 3(149):ra84

PubMed: 21098728 ( click the link to review the publication )

Methods Mol Biol, 2010, 661:107-22

PubMed: 20811979 ( click the link to review the publication )

Purity & Quality Control

Choose Selective MEK Inhibitors

Biological Activity

Description

PD184352 (CI-1040) is an ATP non-competitive MEK1/2 inhibitor with IC50 of 17 nM in cell-based assays, 100-fold more selective for MEK1/2 than MEK5. Phase 2.

Features

First MEK inhibitor to begin clinical development.

Targets

MEK1 ^[1] (Cell-free assay)	MEK2 ^[1] (Cell-free assay)
17 nM	17 nM

In vitro

CI-1040 treatment produces a reduction of pMAPK levels in multiple tumor cells including Colon 26, BX-PC3 pancreatic, A431 cervical, HT-29 colon, ZR-25-1 breast and SKOV-3 ovarian carcinomas. CI-1040 treatment doesn't inhibit the phosphorylation of Jun kinase, p38 kinase or Akt, indicating CI-1040 specifically targets MEK. Inhibition of MAPK activation by CI-1040 prevents cell cycle progression and induces a G1 block. ^[1] The IC50 for inhibition of MEK1 by CI-1040 is 0.3 μM, 15-fold higher than the concentration required to inhibit the EGF-induced activation of ERK2 in Swiss 3T3 cells. These results indicate CI-1040 exerts its effects on cells by suppressing the activation of MKK1, and not by blocking its activity. 2 nM PD184352 inhibits the activation of MKK1 in Swiss 3T3 cells by 50%, while over 100-fold concentration of CI-1040 inhibits MEK1 in vitro. PD184352 also inhibits the Raf-catalysed phosphorylation of MEK1 without any effect on the Raf-catalysed phosphorylation of myelin basic protein. ^[2] CI-1040 inhibits 86% of papillary thyroid carcinoma (PTC) cell growth with the RET/PTC1 rearrangement at 10μM compared with cells treated with DMSO only. CI-1040 shows potent inhibition to PTC cells (BRAF mutation) with GI50 of 52 nM, but low activity to RET/PTC1 rearrangement type with GI50 of 1.1 μM. ^[3] A recent research indicates CI-1040 increases the apoptotic effect of BMS-214662 in a CML blast crisis cell line, K562, and in primary chronic phase CD34+ CML cells. ^[4]

Cell Data

Cell Lines	Assay Type	Activity Description	PMID
H9	NUPhUG1ZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYXoSFhIUUN3ME2wMlAzOjd4IN88US=>	NWnibnlYW0GQR1XS
CHP-212	NUnSRYdZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYTtUY5yUUN3ME2wMlAzQDh3IN88US=>	NF;HNoZUSU6JRWK=
EoL-1-cell	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEfoUZBKSzVyPUCuNFQyPTJizszN	NEPlNoRUSU6JRWK=
DU-4475	NIjXNJZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mn:wTWM2OD1yLkC3OVk6KM7:TR?=	M1;2enNCVkeHUh?=
MMAC-SF	MkLJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXzJR\|UxRTBwMUC5O\|Qh\|ryP	M{DEO3NCVkeHUh?=
AGS	M3nI[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MofHTWM2OD1yLkGxO\|E{KM7:TR?=	NVzrUGlnW0GQR1XS
M14	NEXVU2pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkjmTWM2OD1yLkG1OFY5KM7:TR?=	NHj3N4dUSU6JRWK=
CP50-MEL-B	MlnCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mm\4TWM2OD1yLkG3NlU1KM7:TR?=	MWrTRW5ITVJ?
C32	M{PDbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1rKNmlEPTB;MD6xPVA4OiEQvF2=	M3zZcXNCVkeHUh?=
KMOE-2	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEi5W2tKSzVyPUCuNVk4QTVizszN	MkGzV2FPT0WU
A101D	M{P2UGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MojTTWM2OD1yLkKxOEDPxE1?	MX3TRW5ITVJ?
KM12	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MoX0TWM2OD1yLkK0NFU4KM7:TR?=	MXjTRW5ITVJ?
HSC-4	M2Lac2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUfKNoxwUUN3ME2wMlI1Ozl3IN88US=>	MVvTRW5ITVJ?
NOMO-1	MlzqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXPJR\|UxRTBwMkW3OFIh\|ryP	MXTTRW5ITVJ?
MZ7-mel	M1rtWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mm\zTWM2OD1yLkK2N\|Qh\|ryP	NYLoWXB5W0GQR1XS
ACN	M4n5RWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGG5bVdKSzVyPUCuNlY4OzdizszN	NEm4SYtUSU6JRWK=
MEL-HO	M4\NWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWrJR\|UxRTBwMke2OVIh\|ryP	NVzrWpFMW0GQR1XS
BHT-101	NIi0PVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Ml[4TWM2OD1yLkK4OlA3KM7:TR?=	NUWycXdUW0GQR1XS
SK-MEL-28	M3PTb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYTuToJEUUN3ME2wMlMxPDB7IN88US=>	NXi3d\|UyW0GQR1XS
KG-1	M{jVdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXPJR\|UxRTBwM{C2Olgh\|ryP	NHLaS3RUSU6JRWK=
COLO-679	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXrJR\|UxRTBwM{K3NkDPxE1?	NUPjNoU6W0GQR1XS
SK-MEL-24	NV2yOmRZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXnJR\|UxRTBwM{K4NVMh\|ryP	M1XkV3NCVkeHUh?=
G-361	M{PmVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NV7nU49rUUN3ME2wMlM3Pzl3IN88US=>	MWjTRW5ITVJ?
KY821	NGfue2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2PKOmlEPTB;MD6zO\|kyKM7:TR?=	Ml;WV2FPT0WU
KASUMI-1	M3HGeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFztVYhKSzVyPUCuN\|k6KM7:TR?=	NUPkSpg1W0GQR1XS
HL-60	NXnycVdDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnrBTWM2OD1yLkSxNVA4KM7:TR?=	NUPpNmRiW0GQR1XS
K5	NHv5XnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3X6Z2lEPTB;MD60N\|EyPyEQvF2=	Mm\PV2FPT0WU
KU812	MlPRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlzGTWM2OD1yLkS1Nlk6KM7:TR?=	MUjTRW5ITVJ?
SH-4	MoLDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXHWXVJFUUN3ME2wMlQ3OjV4IN88US=>	M3:2bXNCVkeHUh?=
HTC-C3	Ml7xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkXsTWM2OD1yLkS2OVMyKM7:TR?=	MnruV2FPT0WU
CP66-MEL	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NH7rU2pKSzVyPUCuOFg5ODlizszN	MkTIV2FPT0WU
WM-115	M1j4eGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYm2cJpXUUN3ME2wMlQ6OjV5IN88US=>	NVrrVlBtW0GQR1XS
A2780	NWX0eFQ2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVTJR\|UxRTBwNEm4NlMh\|ryP	MoHqV2FPT0WU
P12-ICHIKAWA	Ml;YS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYXNdphRUUN3ME2wMlYyOjJzIN88US=>	MU\TRW5ITVJ?
HMV-II	NH7ue3lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXrJR\|UxRTBwNkS0OlUh\|ryP	MlXVV2FPT0WU
HT-144	MnzNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlvRTWM2OD1yLk[0OlU4KM7:TR?=	MVvTRW5ITVJ?
LB2518-MEL	NHfPcmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXK2d4RwUUN3ME2wMlcyPjN{IN88US=>	NWixbY5ZW0GQR1XS
NCI-SNU-1	NGjNenlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkHhTWM2OD1yLke1OFM{KM7:TR?=	NIrKXnpUSU6JRWK=
C2BBe1	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYTJR\|UxRTBwOEGwNlMh\|ryP	NH;DRpBUSU6JRWK=
PSN1	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2PpZmlEPTB;MD65OlE6PiEQvF2=	MYPTRW5ITVJ?
UACC-257	NH\lZmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVnJR\|UxRTBwOU[0O\|Mh\|ryP	MVrTRW5ITVJ?
RVH-421	NX;TXYNjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4TofmlEPTB;MD65O\|E5KM7:TR?=	MmWxV2FPT0WU
GP5d	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEfRT\|RKSzVyPUCuPVg{ODhizszN	NWCzUWliW0GQR1XS
TYK-nu	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1f4dWlEPTB;MT6wN\|E4OiEQvF2=	MmnXV2FPT0WU
SK-N-AS	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUHJR\|UxRTFwMEe5OFch\|ryP	MUjTRW5ITVJ?
SW620	Ml\pS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEjLRphKSzVyPUGuNVM2OzRizszN	MlHRV2FPT0WU
HuP-T4	NFvXd2tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHvRZYVKSzVyPUGuNVg{PTlizszN	MlzvV2FPT0WU
A549	NFqw[ZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWPJR\|UxRTFwMUm1O\|Yh\|ryP	M3nteXNCVkeHUh?=
Mewo	NWLENmN5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUTJR\|UxRTFwMkCyO\|Yh\|ryP	MlTqV2FPT0WU
ONS-76	MkDQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVK4eW9lUUN3ME2xMlIzODR7IN88US=>	M2X5[HNCVkeHUh?=
SK-MEL-1	MkXlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NF3JWYtKSzVyPUGuNlM1OTlizszN	MWjTRW5ITVJ?
RCM-1	Mo\rS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{XHbGlEPTB;MT6yOFA1PyEQvF2=	M{TKPHNCVkeHUh?=
H-EMC-SS	M{DCSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFHQcoZKSzVyPUGuNlk3ODhizszN	MXXTRW5ITVJ?
NCI-H2291	NIDN[YNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXjJR\|UxRTFwM{K1N\|Yh\|ryP	MkPrV2FPT0WU
SW1463	NFS3SodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MV3JR\|UxRTFwM{O3NlEh\|ryP	NHz4WZdUSU6JRWK=
LS-411N	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUK0cW0xUUN3ME2xMlQxPTF5IN88US=>	NEPRUXlUSU6JRWK=
BV-173	MkLWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYnue2hpUUN3ME2xMlQ1ODF3IN88US=>	NYPlZWNqW0GQR1XS
LS-513	MonES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXLGfHpxUUN3ME2xMlQ2OTl{IN88US=>	MlzrV2FPT0WU
LoVo	NYTkeXpKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkjMTWM2OD1zLkS2N\|k6KM7:TR?=	MnPBV2FPT0WU
HO-1-N-1	Mn\OS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkPFTWM2OD1zLkWxOlM1KM7:TR?=	MXzTRW5ITVJ?
ML-2	M3Lab2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXjJR\|UxRTFwNUK4Olgh\|ryP	MkPLV2FPT0WU
NCI-H1437	NHnUc4tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{DTVWlEPTB;MT61OVI4PSEQvF2=	M3;YWXNCVkeHUh?=
SW1116	MkK2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWjJR\|UxRTFwNU[zPVgh\|ryP	NHO0NpRUSU6JRWK=
A4-Fuk	MoXyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGLZbpdKSzVyPUGuOVcxPDVizszN	MYPTRW5ITVJ?
HD-MY-Z	MlnOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmDTTWM2OD1zLkW3N\|c3KM7:TR?=	NEnPfnFUSU6JRWK=
SK-MEL-2	NV64Z4Z{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVfJR\|UxRTFwNUe0OVkh\|ryP	M131[HNCVkeHUh?=
RT-112	MnfIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MofFTWM2OD1zLkW4PVUzKM7:TR?=	Mlj5V2FPT0WU
COLO-829	MlPVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlSwTWM2OD1zLk[yNlMzKM7:TR?=	MXPTRW5ITVJ?
OVCAR-5	NHfTOodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYjRU\|czUUN3ME2xMlc4Pjh5IN88US=>	MnzsV2FPT0WU
NB69	MlnXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEHaXGlKSzVyPUGuO\|g1PjlizszN	M1niTHNCVkeHUh?=
NCI-H292	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1HzO2lEPTB;MT64OlY6QSEQvF2=	M4HrTHNCVkeHUh?=
LOXIMVI	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4TYS2lEPTB;MT64PVQzPyEQvF2=	NXT3T5p6W0GQR1XS
BPH-1	NWO3WVdyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVvTfHJjUUN3ME2xMlg6PTlzIN88US=>	M3j4XXNCVkeHUh?=
A375	Mo[4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFroPIhKSzVyPUGuPFk4OTRizszN	MYXTRW5ITVJ?
LCLC-97TM1	NHyyVYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NV3LZYFTUUN3ME2xMlkzOjV4IN88US=>	MX7TRW5ITVJ?
RXF393	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHzoe\|FKSzVyPUGuPVc5QDdizszN	MXLTRW5ITVJ?
HCC70	Ml:zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlXxTWM2OD1{LkCyOFI3KM7:TR?=	NXq5[Y9HW0GQR1XS
EM-2	M1vJdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnW3TWM2OD1{LkC3NVk5KM7:TR?=	MmXVV2FPT0WU
MZ2-MEL	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEHtcFVKSzVyPUKuNVEyOjdizszN	NFHCPWtUSU6JRWK=
HN	Mne5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmfVTWM2OD1{LkG2Nlc5KM7:TR?=	NXe0cFE4W0GQR1XS
A2058	M4ThfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NULCS45qUUN3ME2yMlE6Ojd7IN88US=>	M2nDfXNCVkeHUh?=
NB7	M37XWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXP5fpk3UUN3ME2yMlM1ODh4IN88US=>	M1XNTHNCVkeHUh?=
DOK	M2\ibGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmHETWM2OD1{LkO1O\|c{KM7:TR?=	MUfTRW5ITVJ?
CAL-27	MnXvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUfWVmlFUUN3ME2yMlM6OjN4IN88US=>	Mnz5V2FPT0WU
BB65-RCC	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkXVTWM2OD1{LkSwOlc1KM7:TR?=	NUPDb5NuW0GQR1XS
RD	M4THS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MX3JR\|UxRTJwNES3NlMh\|ryP	NE\MdmJUSU6JRWK=
KNS-62	NFXjUJdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Ml7QTWM2OD1{LkWxNVY1KM7:TR?=	MYPTRW5ITVJ?
EW-13	NXfDOYdZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXqzRXFFUUN3ME2yMlU3OzN7IN88US=>	MkfXV2FPT0WU
DB	MmHjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXTJR\|UxRTJwNUi3PFgh\|ryP	M1Hrc3NCVkeHUh?=
HCC2218	M17IbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4L5VGlEPTB;Mj62OFc4QCEQvF2=	M1zQXXNCVkeHUh?=
L-363	NVjFb2xCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWjueZJGUUN3ME2yMlc1OzdizszN	M2jnNnNCVkeHUh?=
CHL-1	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlzVTWM2OD1{LkiwO\|g2KM7:TR?=	MmSzV2FPT0WU
BFTC-905	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4WwNWlEPTB;Mj64NlU{KM7:TR?=	MX7TRW5ITVJ?
HCE-T	NIPlSWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVfJR\|UxRTJwOEOyOlQh\|ryP	M2n5SXNCVkeHUh?=
COLO-792	NVPFdJB{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXrDWGpkUUN3ME2yMlg1ODJ5IN88US=>	MV3TRW5ITVJ?
LB2241-RCC	MnrmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MU\JR\|UxRTJwOEW4PVMh\|ryP	M4O0eXNCVkeHUh?=
CAL-39	M1zzWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2TJZ2lEPTB;Mj64PVk6QSEQvF2=	NVjzdoYyW0GQR1XS
T-24	NEPqSpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4XvS2lEPTB;Mj65NVEyOiEQvF2=	NYXHdmRnW0GQR1XS
NCI-H727	M1PzXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWKxVmJ3UUN3ME2yMlkyPzl4IN88US=>	NEP5e5lUSU6JRWK=
Ca9-22	NXLkNpBmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGPYU\|JKSzVyPUKuPVczPTVizszN	NF36cHFUSU6JRWK=
MIA-PaCa-2	NFzIbnNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NELOOplKSzVyPUOuNFA4QDFizszN	MnnHV2FPT0WU
HT-1080	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXnsN2dkUUN3ME2zMlAyQTl5IN88US=>	MkPHV2FPT0WU
D-423MG	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3vLVWlEPTB;Mz6wO\|c2OyEQvF2=	NEPtd4tUSU6JRWK=
LAMA-84	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnHlTWM2OD1\|LkGzOVgh\|ryP	NFG3S5RUSU6JRWK=
SW780	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGrUSpdKSzVyPUOuNVQzOjlizszN	MYLTRW5ITVJ?
KU-19-19	M4\kPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnTHTWM2OD1\|LkG3NFM1KM7:TR?=	MUTTRW5ITVJ?
COLO-741	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mm\UTWM2OD1\|LkG4Olc{KM7:TR?=	NWnkUZhtW0GQR1XS
HSC-3	NWPiUIV2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mo\GTWM2OD1\|LkKzNVUyKM7:TR?=	M{XVNHNCVkeHUh?=
SN12C	NI[yR4VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2jzXGlEPTB;Mz6yOFcxOSEQvF2=	MUDTRW5ITVJ?
786-0	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3m1TWlEPTB;Mz6yO\|I1OyEQvF2=	NUPBUWFoW0GQR1XS
GAK	MlrmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NV[xWllpUUN3ME2zMlMzPTZzIN88US=>	Mor4V2FPT0WU
PANC-03-27	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2PTbmlEPTB;Mz6zOVA1PSEQvF2=	NUTpSmo4W0GQR1XS
CTB-1	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXzpc3VEUUN3ME2zMlQ4ODR5IN88US=>	Mo[0V2FPT0WU
A427	NXLmRYVDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnjSTWM2OD1\|LkW5OVU3KM7:TR?=	M165WHNCVkeHUh?=
EGI-1	M4LaUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3HMd2lEPTB;Mz62NFU5OyEQvF2=	M1\lSXNCVkeHUh?=
U-2-OS	MnOwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIHRdotKSzVyPUOuOlczPTZizszN	MVHTRW5ITVJ?
NCI-SNU-5	NI\oeFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4HERmlEPTB;Mz62O\|c{KM7:TR?=	MWHTRW5ITVJ?
SK-LU-1	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFv2O\|RKSzVyPUOuOlg4QThizszN	MU\TRW5ITVJ?
697	NHvPOllIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmCzTWM2OD1\|Lk[5OlA{KM7:TR?=	Ml7SV2FPT0WU
HPAF-II	M4Lidmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUTWNJFMUUN3ME2zMlc2PDlizszN	MVXTRW5ITVJ?
NCI-H2087	NXj0fZg5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYLpTpZDUUN3ME2zMlg1Pjd{IN88US=>	NUXvcIs6W0GQR1XS
SK-MEL-3	NGDRU\|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHnPWm1KSzVyPUOuPFUyPTRizszN	NXOzOXdVW0GQR1XS
CGTH-W-1	NXn0XFhZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1rRW2lEPTB;Mz64OVczPSEQvF2=	MkHKV2FPT0WU
8505C	NXS3bFloT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWXJR\|UxRTNwOUCwO\|gh\|ryP	Mnf1V2FPT0WU
GAMG	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NV;rOXBbUUN3ME20MlAzOzd5IN88US=>	MkWyV2FPT0WU
SW626	M1qyZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NV;Tc3JPUUN3ME20MlA1PDhizszN	MWnTRW5ITVJ?
CAL-62	MoS5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NITndXlKSzVyPUSuNFc1OyEQvF2=	NH3zXIlUSU6JRWK=
MHH-PREB-1	M3rvR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnnpTWM2OD12LkGyNVEyKM7:TR?=	M2Tae3NCVkeHUh?=
RPMI-7951	NUDZV5hDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYTBSG03UUN3ME20MlI2PTh7IN88US=>	NF32RVZUSU6JRWK=
HOP-92	NWX0fpB3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlX2TWM2OD12LkK1Olch\|ryP	NFrablNUSU6JRWK=
MDA-MB-231	MoG2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnnsTWM2OD12LkK5NlI{KM7:TR?=	MVPTRW5ITVJ?
LAN-6	Ml2xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2LqT2lEPTB;ND6zNVY{PyEQvF2=	NVKwXmxVW0GQR1XS
ALL-PO	NWPz[JlyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXfJR\|UxRTRwM{[xOVYh\|ryP	MmL1V2FPT0WU
HH	NInyUpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEXBS25KSzVyPUSuOFE2QTdizszN	MUjTRW5ITVJ?
IGROV-1	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4DnSmlEPTB;ND60OVE4OSEQvF2=	MW\TRW5ITVJ?
NCI-H358	M3r2NGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mn7kTWM2OD12LkS1N\|g2KM7:TR?=	MYXTRW5ITVJ?
NB5	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mk[5TWM2OD12Lk[wN\|Y6KM7:TR?=	M3m2N3NCVkeHUh?=
NCI-H747	NVfPdnVyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUDLXJR7UUN3ME20MlY5QDB5IN88US=>	NWnaOpZmW0GQR1XS
NH-12	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVnJR\|UxRTRwN{G2NlUh\|ryP	Ml7TV2FPT0WU
LB1047-RCC	MmjqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NH7XWohKSzVyPUSuO\|M5OTVizszN	NYm0[HpVW0GQR1XS
EFO-27	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4OyOmlEPTB;ND63PFY3PyEQvF2=	MYLTRW5ITVJ?
EPLC-272H	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnzLTWM2OD12Lkm5OlY6KM7:TR?=	Ml;WV2FPT0WU
CAL-54	NI\u[4hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2\RPGlEPTB;NT6wNlY6PSEQvF2=	NGTOcnpUSU6JRWK=
H4	M2PTO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MknWTWM2OD13LkC0NlU2KM7:TR?=	NIiwbIpUSU6JRWK=
MOLT-13	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGjKSXFKSzVyPUWuNFY4PzZizszN	NVfCSJNqW0GQR1XS
CAL-33	MkDBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnTFTWM2OD13LkGyN\|E4KM7:TR?=	NXzCNIR2W0GQR1XS
23132-87	NF\ne5lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGnzc5dKSzVyPUWuNVY5PzJizszN	M{\ycnNCVkeHUh?=
UM-UC-3	M3PsUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3Lib2lEPTB;NT6xPFA1PyEQvF2=	NF3PWHNUSU6JRWK=
HuH-7	Ml\VS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFHxdIRKSzVyPUWuNlcyPDdizszN	NVnFOGhRW0GQR1XS
BCPAP	M3vMd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUnJR\|UxRTVwM{K5Olkh\|ryP	MYrTRW5ITVJ?
AsPC-1	M1HTcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWDT[mlOUUN3ME21MlM3PzZ\|IN88US=>	NGHOZ3pUSU6JRWK=
NCI-H1155	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkLVTWM2OD13LkSwNFUyKM7:TR?=	MXHTRW5ITVJ?
GT3TKB	NGj6O4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXvNco9bUUN3ME21MlQ3PTl6IN88US=>	MVLTRW5ITVJ?
HCC2998	M1POfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUS0dWNNUUN3ME21MlQ6OTB7IN88US=>	NWPO[3ZDW0GQR1XS
NUGC-3	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Ml3TTWM2OD13LkS5N\|AzKM7:TR?=	Mkn6V2FPT0WU
Hs-578-T	MkjpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFHxcYVKSzVyPUWuOVM4QTRizszN	NXvrfIlVW0GQR1XS
FADU	NEHOXmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVfJR\|UxRTVwNUW3NlYh\|ryP	NWHOVnVCW0GQR1XS
NBsusSR	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NH7VSnNKSzVyPUWuOVcyPTVizszN	M1uwTXNCVkeHUh?=
ME-180	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGO3bXRKSzVyPUWuOVgxQTJizszN	M1mwNHNCVkeHUh?=
SW1710	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2\5T2lEPTB;NT62NVY2PCEQvF2=	MXfTRW5ITVJ?
HuP-T3	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mn3QTWM2OD13Lk[yNFI6KM7:TR?=	Ml:0V2FPT0WU
HOS	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mki0TWM2OD13Lk[yPVI{KM7:TR?=	M1PXcHNCVkeHUh?=
PA-1	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnzQTWM2OD13Lk[0NlY2KM7:TR?=	MVvTRW5ITVJ?
LU-99A	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEfHdGNKSzVyPUWuOlY1PTFizszN	MlzjV2FPT0WU
RS4-11	NUPXO\|dyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1nMeWlEPTB;NT62Olc4PSEQvF2=	NILGXJpUSU6JRWK=
TE-8	NHrJO\|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYD2XZFOUUN3ME21MlY5PTN5IN88US=>	NXS0dYs3W0GQR1XS
RERF-LC-MS	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmnHTWM2OD13Lk[4PFA{KM7:TR?=	MkTTV2FPT0WU
MEL-JUSO	NYPPSYhGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFnOWYNKSzVyPUWuO\|M4QCEQvF2=	M{m2cXNCVkeHUh?=
SK-MES-1	NX:xTXJyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWXJR\|UxRTVwOEO1Nlgh\|ryP	Mn:yV2FPT0WU
D-263MG	NV;Y[GhpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3rZe2lEPTB;NT64PFM2OSEQvF2=	NGGzcXZUSU6JRWK=
NB10	Mn;PS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NU\qZXBpUUN3ME21Mlg6PDZizszN	NEHKfIVUSU6JRWK=
SK-HEP-1	M3H5fmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXXJR\|UxRTVwOUO0O\|Eh\|ryP	NF3CV4dUSU6JRWK=
HT-29	M{fVXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M17WUmlEPTB;NT65PFEyQCEQvF2=	M1HQfnNCVkeHUh?=
KYSE-140	MnfsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3TCUmlEPTB;Nj6wNlE5OiEQvF2=	NXK2[Wp6W0GQR1XS
NCI-H1666	MmTOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnPGTWM2OD14LkC4OFYyKM7:TR?=	MXfTRW5ITVJ?
NCI-H1304	M2T6Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGfPdnpKSzVyPU[uNVk6PCEQvF2=	MX\TRW5ITVJ?
RPMI-8866	M3faW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEnaVW1KSzVyPU[uNlE{OTNizszN	NVjNOlZxW0GQR1XS
MV-4-11	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4exUGlEPTB;Nj6yN\|E6QSEQvF2=	M4LENHNCVkeHUh?=
A431	M1HXOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NX;LW\|dnUUN3ME22MlI1Ojl4IN88US=>	MnT6V2FPT0WU
PANC-10-05	NFL0R5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFW5TGxKSzVyPU[uNlg{PjNizszN	Mn7GV2FPT0WU
TK10	MkexS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MU\JR\|UxRTZwM{K2NFQh\|ryP	NYmyVGhzW0GQR1XS
NCI-H1975	NHfIfWRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVjJR\|UxRTZwNEeyNVUh\|ryP	MnzkV2FPT0WU
A172	MnnGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlzqTWM2OD14LkS5NVc3KM7:TR?=	M2HlN3NCVkeHUh?=
D-566MG	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFG5d3BKSzVyPU[uOVQ{ODNizszN	MWLTRW5ITVJ?
NCI-H2122	MnrVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{TDTWlEPTB;Nj62NVUzQCEQvF2=	NFzJelBUSU6JRWK=
COR-L105	NIHvSI1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWXJR\|UxRTZwNkWyO\|Uh\|ryP	NVLnc\|hYW0GQR1XS
AN3-CA	NEPFOYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUfv[HJUUUN3ME22MlY5PjRzIN88US=>	Mkn5V2FPT0WU
Calu-6	NX\KTJRwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFLwWY9KSzVyPU[uO\|k3QThizszN	NH3LemRUSU6JRWK=
HCT-116	M1XaVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NX;ES4V{UUN3ME22MlgyOjZ2IN88US=>	MWjTRW5ITVJ?
MHH-NB-11	NXznbJdDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWfJR\|UxRTZwOEWwNFIh\|ryP	NVvkcFltW0GQR1XS
MFE-280	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXHvbVFYUUN3ME22Mlg2QTh\|IN88US=>	MofNV2FPT0WU
SW1088	M37Tdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MU\JR\|UxRTZwOUG5NVMh\|ryP	MYTTRW5ITVJ?
SW48	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVvJR\|UxRTZwOUS1NUDPxE1?	NWS3TpE3W0GQR1XS
HuCCT1	Mmj2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHfBcnNKSzVyPUeuNFExOzdizszN	NWXafm5yW0GQR1XS
ACHN	NEH4fGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWjJR\|UxRTdwMEK5OFMh\|ryP	M{fESXNCVkeHUh?=
8305C	Mke1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWTJR\|UxRTdwMEm5PVUh\|ryP	M2fHWHNCVkeHUh?=
DoTc2-4510	M2L0UGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnraTWM2OD15LkGyNVUh\|ryP	M3nBeHNCVkeHUh?=
COR-L23	Ml3HS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWnJR\|UxRTdwMkS0NkDPxE1?	MmDpV2FPT0WU
SK-MEL-30	MmD1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHHONlVKSzVyPUeuNlUxQDNizszN	M37iWHNCVkeHUh?=
BE-13	NIfJRXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1zwcGlEPTB;Nz6zN\|g{PCEQvF2=	NHS2V3RUSU6JRWK=
GR-ST	NEXHW41Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVKyU\|ZYUUN3ME23MlQxOTd2IN88US=>	Mk\DV2FPT0WU
LU-135	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4rtNWlEPTB;Nz61OVk{QSEQvF2=	MUHTRW5ITVJ?
U-266	NV3OW2FsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWnG[4dNUUN3ME23MlU3Ojh4IN88US=>	MVLTRW5ITVJ?
NCI-H1355	Mk\KS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXrJR\|UxRTdwNUi2N\|Uh\|ryP	NGnmOmRUSU6JRWK=
NB14	MoLiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4OxTGlEPTB;Nz62OlY1OiEQvF2=	M{P2bXNCVkeHUh?=
SCC-25	NXnPOFFoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYXJR\|UxRTdwN{C5JO69VQ>?	NH;kOXFUSU6JRWK=
COLO-678	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3q2eWlEPTB;Nz63NVA4PiEQvF2=	M33MXnNCVkeHUh?=
TGBC1TKB	Mo\PS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXnBZpdHUUN3ME23Mlg6Ozl6IN88US=>	M1PEd3NCVkeHUh?=
IST-MEL1	MnzBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmnRTWM2OD16LkCwOFA3KM7:TR?=	M{HJUnNCVkeHUh?=
ECC10	NFXKdnNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmX6TWM2OD16LkCzN\|k2KM7:TR?=	NIHVZVdUSU6JRWK=
EW-16	NITl[4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXi0dYk4UUN3ME24MlA5PDR3IN88US=>	NXvpcIR2W0GQR1XS
DOHH-2	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkWzTWM2OD16LkKwNFk2KM7:TR?=	MnHtV2FPT0WU
NCI-H1581	Moj0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NH7HW4VKSzVyPUiuNlY{OjNizszN	M3\seHNCVkeHUh?=
TE-5	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1\rWmlEPTB;OD60NlQzQSEQvF2=	NVe3S\|B5W0GQR1XS
CAKI-1	Mn\hS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NV6yZ3JXUUN3ME24MlU4OjJ{IN88US=>	NVW4V5ZwW0GQR1XS
A673	NVzK[3RGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVHJR\|UxRThwNkOyNFIh\|ryP	M{mydXNCVkeHUh?=
CAL-12T	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2PnVWlEPTB;OD62OVc2OyEQvF2=	MnSwV2FPT0WU
DBTRG-05MG	Ml3IS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVfJR\|UxRThwN{S4OVkh\|ryP	Ml;RV2FPT0WU
SK-N-FI	NUHiN41PT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVHsR4NFUUN3ME24MlgyOzd7IN88US=>	NUnjW3pkW0GQR1XS
K-562	NELwdFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1XSWGlEPTB;OD64N\|k2PyEQvF2=	NF\k[mhUSU6JRWK=
SBC-1	NHy2T5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MoW4TWM2OD16Lki2OlQ2KM7:TR?=	NIXxPZZUSU6JRWK=
ES4	NFHBXY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVLJR\|UxRThwOE[4PFQh\|ryP	NV\6SGRxW0GQR1XS
MS-1	NHvvOW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVfkdJFPUUN3ME24Mlg4PTF5IN88US=>	NGWwW3ZUSU6JRWK=
RKO	MlmwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NH:yV3pKSzVyPUiuPFkxPTdizszN	MVjTRW5ITVJ?
NCI-H1693	NV;HZ3NqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkDITWM2OD16LkmyNVch\|ryP	NIjGR2NUSU6JRWK=
SW954	NInPSIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1Hzb2lEPTB;OD65Olk4QCEQvF2=	NXi2emJNW0GQR1XS
SK-UT-1	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnvJTWM2OD16Lkm3Olg{KM7:TR?=	MnHCV2FPT0WU
T98G	M2rzTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{SxTmlEPTB;OD65PVg1PiEQvF2=	MYfTRW5ITVJ?
NCI-H2126	NW\Ielh4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NELlU25KSzVyPUmuNFA5OjZizszN	NVPtTYdFW0GQR1XS
TE-12	NXPxOHlsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXvJR\|UxRTlwMEOzOlch\|ryP	M1HFd3NCVkeHUh?=
DK-MG	NX[xPIlZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MY\JR\|UxRTlwMkGxPVEh\|ryP	NWHiV5RSW0GQR1XS
MEG-01	M4DZNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVPJR\|UxRTlwMkS5N\|Eh\|ryP	MoDJV2FPT0WU
HCC1937	NHjDOIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmjUTWM2OD17LkK5NFkyKM7:TR?=	MX;TRW5ITVJ?
MKN45	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYHlNIZ[UUN3ME25MlQ2ODZ3IN88US=>	NW\sfmdTW0GQR1XS
NCI-H1792	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MU\JR\|UxRTlwNEWyNVkh\|ryP	MYTTRW5ITVJ?
SW1417	MmLVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWTJR\|UxRTlwNU[4N\|ch\|ryP	MVrTRW5ITVJ?
639-V	MkXiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3vKZ2lEPTB;OT62OFM5QCEQvF2=	NXXtNJZTW0GQR1XS
P30-OHK	M4jiNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlfFTWM2OD17Lk[1N\|E3KM7:TR?=	MX\TRW5ITVJ?
YKG-1	M4LBT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4HwWWlEPTB;OT63OVA{OyEQvF2=	MnrVV2FPT0WU
KGN	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWDmUWIxUUN3ME25Mlg{Pzl3IN88US=>	NHn5N4hUSU6JRWK=
MSTO-211H	M1H5V2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3POTWlEPTB;OT65OVUzQSEQvF2=	M1\ZdHNCVkeHUh?=
NCI-H1573	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3X0R2lEPTB;MUCuNVU4PCEQvF2=	M1rCd3NCVkeHUh?=
NCI-H720	NY[5fGRKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlvXTWM2OD1zMD6xPVg6KM7:TR?=	NX\zdZNpW0GQR1XS
KARPAS-45	Mmr0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MW\JR\|UxRTFyLkK3PVUh\|ryP	M3HOPHNCVkeHUh?=
MDA-MB-175-VII	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NH\YbFdKSzVyPUGwMlQ5KM7:TR?=	NXe4SmVlW0GQR1XS
SK-NEP-1	NVzrZmg1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnWwTWM2OD1zMD60PVgyKM7:TR?=	M2PQ[3NCVkeHUh?=
MKN28	MkfaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlnSTWM2OD1zMD61NVgh\|ryP	NWr3VVNlW0GQR1XS
KYSE-520	M2G4Z2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1KwcWlEPTB;MUCuOVIh\|ryP	NHvzc4pUSU6JRWK=
KE-37	NFTsbHJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mm\mTWM2OD1zMD61NlczKM7:TR?=	MkTmV2FPT0WU
VA-ES-BJ	M3XQTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXfmbnVxUUN3ME2xNE42PjdizszN	NWXzepNLW0GQR1XS
CCRF-CEM	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{HBTGlEPTB;MUCuOVY5PCEQvF2=	M4GxfXNCVkeHUh?=
GMS-10	NWXPVVVVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4DkZ2lEPTB;MUCuOlA6PCEQvF2=	NVHlN3Q{W0GQR1XS
NCI-H1623	MnG1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFi1UohKSzVyPUGwMlY{PzlizszN	MWPTRW5ITVJ?
NEC8	NUfZVFloT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1rDcWlEPTB;MUCuO\|c4OyEQvF2=	MV;TRW5ITVJ?
MOLT-16	M4mwd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmfRTWM2OD1zMD64NVE{KM7:TR?=	MXHTRW5ITVJ?
DJM-1	M2fycWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2\kNGlEPTB;MUGuNFM4QSEQvF2=	MXjTRW5ITVJ?
U251	NV\WeoI6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MonPTWM2OD1zMT6wOFIh\|ryP	NEjVT4ZUSU6JRWK=
SBC-5	MlTFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkG5TWM2OD1zMT6xOFY4KM7:TR?=	MmK4V2FPT0WU
SW756	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlnQTWM2OD1zMT6yNVU1KM7:TR?=	NY\nW2ZRW0GQR1XS
KS-1	MnjKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHvmSGVKSzVyPUGxMlI3OTlizszN	MkLNV2FPT0WU
SF295	NUj3NoFxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWTJR\|UxRTFzLkOxNFQh\|ryP	NF7ZTIhUSU6JRWK=
YH-13	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Ml[0TWM2OD1zMT6zNlY4KM7:TR?=	MkLDV2FPT0WU
SW837	Moe0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmD0TWM2OD1zMT6zOVA3KM7:TR?=	NUPM[3RLW0GQR1XS
KYSE-450	MmK5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEWzc4VKSzVyPUGxMlQxPTdizszN	M3TEOnNCVkeHUh?=
KYSE-180	NGnPeYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Ml;RTWM2OD1zMT60PFIh\|ryP	M1XScXNCVkeHUh?=
S-117	NIrYbpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NF;pfGtKSzVyPUGxMlQ5QTZizszN	MXzTRW5ITVJ?
KOSC-2	NUPmfYh{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M37IdWlEPTB;MUGuOlIzOiEQvF2=	M3jkTnNCVkeHUh?=
KYSE-270	M1fNS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUHJR\|UxRTFzLki3OFUh\|ryP	NXfvV3NOW0GQR1XS
D-336MG	M3LZUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFnhWplKSzVyPUGxMlkxPzVizszN	MUHTRW5ITVJ?
KALS-1	NEPRSZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXH1bFJwUUN3ME2xNk4xODF4IN88US=>	NVPkSYZwW0GQR1XS
LB373-MEL-D	M3vIR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIjCOZBKSzVyPUGyMlA2OzNizszN	MlTGV2FPT0WU
HLE	MmfNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXvYbG9RUUN3ME2xNk4xPTh3IN88US=>	M{HKenNCVkeHUh?=
SJSA-1	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmO3TWM2OD1zMj6wO\|M2KM7:TR?=	NHe2OpBUSU6JRWK=
SW1990	MmDUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{TWdWlEPTB;MUKuNFkyOSEQvF2=	NYLQZYNRW0GQR1XS
NOS-1	NXf3[5lbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4PKWGlEPTB;MUKuNVM2OiEQvF2=	M4jUS3NCVkeHUh?=
GI-ME-N	NELyZpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4PaNmlEPTB;MUKuNlE3OyEQvF2=	NELhVGtUSU6JRWK=
NCI-H1703	NVLZfoFVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVrJR\|UxRTF{LkK2NVYh\|ryP	NVW0Z4hKW0GQR1XS
ES7	M4\ZfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVjJR\|UxRTF{LkK3NlQh\|ryP	Mly2V2FPT0WU
KYSE-510	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NI\LNGFKSzVyPUGyMlUxPzlizszN	Mn72V2FPT0WU
BHY	Ml64S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWXJR\|UxRTF{LkWzNFch\|ryP	MY\TRW5ITVJ?
TCCSUP	M1PvXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVWxRWNsUUN3ME2xNk42PzV5IN88US=>	MnrJV2FPT0WU
HSC-2	NHHvemZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MljiTWM2OD1zMj61PVk3KM7:TR?=	M37BUXNCVkeHUh?=
BEN	NVLtfod2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWnJR\|UxRTF{Lk[xOFMh\|ryP	M{PoSnNCVkeHUh?=
769-P	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGDBZ4RKSzVyPUGyMlc6OjRizszN	MWLTRW5ITVJ?
HT	NVW4ZYNnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUXJR\|UxRTF{LkizOFYh\|ryP	MYfTRW5ITVJ?
LXF-289	NGG5cpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3zMemlEPTB;MUKuPVU{OSEQvF2=	MnzuV2FPT0WU
OVCAR-3	M4myUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NY\HVmo5UUN3ME2xNk46PTZ5IN88US=>	MlTaV2FPT0WU
ATN-1	M{fSVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3jyNWlEPTB;MUOuNFE5PCEQvF2=	NGTxXo5USU6JRWK=
8-MG-BA	NFq0VJdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVfxXmRUUUN3ME2xN{4xPDV3IN88US=>	M4W3NnNCVkeHUh?=
SW13	M{TifGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NW\HOpFQUUN3ME2xN{4yOTZ3IN88US=>	NV\VOHJZW0GQR1XS
NCI-H1092	MnzyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{PBNGlEPTB;MUOuNVYzKM7:TR?=	M2XMUXNCVkeHUh?=
OAW-42	M{HMd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mm\5TWM2OD1zMz6xPVM4KM7:TR?=	M3fvfXNCVkeHUh?=
NCI-H2452	M2\Xdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2j2PGlEPTB;MUOuNlE4PSEQvF2=	NES4Z5JUSU6JRWK=
CAPAN-1	MnTlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXz5SolHUUN3ME2xN{42PTF2IN88US=>	M3n4RXNCVkeHUh?=
NCI-H2009	M13QTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVPJR\|UxRTF\|LkW5NVkh\|ryP	MkftV2FPT0WU
SF268	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1zxVmlEPTB;MUOuOlMzPiEQvF2=	MmPXV2FPT0WU
GCIY	MoPlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIPFdI9KSzVyPUGzMlY6OjdizszN	NXfMfppzW0GQR1XS
OS-RC-2	M4Tadmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVXNWHFCUUN3ME2xN{46PTBzIN88US=>	MnvqV2FPT0WU
GCT	NYCzV4dpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXu4OoNDUUN3ME2xN{46Pjl5IN88US=>	MX;TRW5ITVJ?
NB17	M4jMXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mn3VTWM2OD1zND6wPFUh\|ryP	MUfTRW5ITVJ?
NCI-H2030	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlTzTWM2OD1zND6xOFY2KM7:TR?=	M4TqU3NCVkeHUh?=
HC-1	NFi2TI9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlftTWM2OD1zND6yNFg4KM7:TR?=	NHLXV2hUSU6JRWK=
QIMR-WIL	NUfEdIx[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkHiTWM2OD1zND6zOFEzKM7:TR?=	M3XkbXNCVkeHUh?=
Capan-2	NXPSeoJqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVzJR\|UxRTF2LkO3NVQh\|ryP	MYXTRW5ITVJ?
BALL-1	M4DSOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFrBb\|lKSzVyPUG0MlQ3PjVizszN	NUjNTm51W0GQR1XS
LS-1034	MoOwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYnDc4pnUUN3ME2xOE43OTV{IN88US=>	NF[4TlVUSU6JRWK=
U-118-MG	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXnqempxUUN3ME2xOE43OzFizszN	NGPYPYZUSU6JRWK=
NCI-H630	NI[5d4hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUTJR\|UxRTF2Lk[1Olgh\|ryP	MVLTRW5ITVJ?
OVCAR-8	NFvyNnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVfjO\|ExUUN3ME2xOE44OjBzIN88US=>	M2fSOHNCVkeHUh?=
NCI-H2347	NHXFW5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnL4TWM2OD1zND64NlMh\|ryP	MYTTRW5ITVJ?
BT-549	Mk\yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkK0TWM2OD1zND64Nlg1KM7:TR?=	NGrrS4hUSU6JRWK=
LB831-BLC	MojwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MoLiTWM2OD1zND64PVM1KM7:TR?=	M1HZZ3NCVkeHUh?=
NCI-H661	M1TCcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXvDSGpzUUN3ME2xOE46PTlizszN	NGrY[4RUSU6JRWK=
MKN7	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NH7oPW9KSzVyPUG1MlAxQTNizszN	NF3GPYRUSU6JRWK=
U-87-MG	NWfGNI54T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYi0WWF[UUN3ME2xOU4xQDl5IN88US=>	Mm\pV2FPT0WU
OVCAR-4	NHjLWHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2jZ[GlEPTB;MUWuNVQzPCEQvF2=	NFviNYNUSU6JRWK=
OE33	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXzDeYZFUUN3ME2xOU4yPzFzIN88US=>	M4DIW3NCVkeHUh?=
EC-GI-10	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmfVTWM2OD1zNT6yN\|U4KM7:TR?=	MYnTRW5ITVJ?
AM-38	M4\MW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3T5NWlEPTB;MUWuNlcyPyEQvF2=	MoT0V2FPT0WU
NCI-H1563	Mlr5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVfjT4tYUUN3ME2xOU4{PDlizszN	NFHUfoZUSU6JRWK=
SCC-4	M2\ZOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYXJR\|UxRTF3LkSxNFMh\|ryP	M4T3OnNCVkeHUh?=
Detroit562	NGToe5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHTnb4FKSzVyPUG1MlQ2PDdizszN	MX7TRW5ITVJ?
PC-14	M1HHcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M331U2lEPTB;MUWuOFg3PiEQvF2=	M1;IdXNCVkeHUh?=
ES3	M1\6Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkW3TWM2OD1zNT61N\|Yh\|ryP	MoHkV2FPT0WU
OCI-AML2	NH\4U2pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2CyO2lEPTB;MUWuO\|YyPCEQvF2=	M2LG[nNCVkeHUh?=
LU-134-A	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2rVZ2lEPTB;MUWuPVAyQCEQvF2=	NEjEbY5USU6JRWK=
SAS	NXK3SZY1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NH3iVIVKSzVyPUG1Mlk{PzNizszN	NF\rUZBUSU6JRWK=
TGBC11TKB	MlrVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MULJR\|UxRTF3Lkm0NVQh\|ryP	NV7JeI9xW0GQR1XS
HOP-62	NWjHNYYxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MV;JR\|UxRTF3Lkm1PVch\|ryP	NYHsNIEyW0GQR1XS
G-401	Ml3SS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXPJR\|UxRTF3Lkm2OFkh\|ryP	NIfyO4ZUSU6JRWK=
NCI-H28	MmHnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2LQ[WlEPTB;MU[uNFg2PiEQvF2=	NWf6d3A1W0GQR1XS
A204	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIDKcmxKSzVyPUG2MlIxODZizszN	NXvDTlZuW0GQR1XS
NCI-H1299	NGL0SlZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkfvTWM2OD1zNj6yNlkyKM7:TR?=	NIGzToVUSU6JRWK=
VMRC-RCZ	Mn3ZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXLoWIVzUUN3ME2xOk4zPTl{IN88US=>	NWrvNYt7W0GQR1XS
BxPC-3	MoG4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2iwOmlEPTB;MU[uNlg2PiEQvF2=	MX\TRW5ITVJ?
NCI-H2228	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4X6SmlEPTB;MU[uOVE2QCEQvF2=	MnztV2FPT0WU
NCI-H23	NVLOWllqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYfjeHJQUUN3ME2xOk43ODd6IN88US=>	MmfhV2FPT0WU
NKM-1	MoDJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkLOTWM2OD1zNz6wNVg6KM7:TR?=	MkGxV2FPT0WU
KYSE-70	MmLCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYPpb\|k{UUN3ME2xO{4zQDlizszN	NIS4XWpUSU6JRWK=
BB49-HNC	NIPPWIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MljhTWM2OD1zNz61Olg3KM7:TR?=	MYDTRW5ITVJ?
SCC-15	M{C0UGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{H2TWlEPTB;MUeuPFQ4OyEQvF2=	M3zSeHNCVkeHUh?=
D-247MG	NEHqeXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Ml\mTWM2OD1zNz65NlQ4KM7:TR?=	NFXGXJVUSU6JRWK=
BB30-HNC	NET3XphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVzJR\|UxRTF6LkCzNVgh\|ryP	MlixV2FPT0WU
CAL-85-1	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkPLTWM2OD1zOD6xPFA6KM7:TR?=	MVTTRW5ITVJ?
HT-3	Mmi0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXLJR\|UxRTF6LkO5O\|ch\|ryP	MVHTRW5ITVJ?
KYSE-410	NFuzSZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MX7JR\|UxRTF6LkS1O\|ch\|ryP	MV;TRW5ITVJ?
SW982	M2DIbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEXnWpNKSzVyPUG4MlU3PDlizszN	M{HQWnNCVkeHUh?=
SW962	NEHoO3RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUTNd5JDUUN3ME2xPE42PzB{IN88US=>	MX3TRW5ITVJ?
Ramos-2G6-4C10	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1rwV2lEPTB;MUiuOVkzPyEQvF2=	MVrTRW5ITVJ?
OC-314	NFT4XIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUfJR\|UxRTF6LkezPFQh\|ryP	MoHnV2FPT0WU
LS-123	MkLhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHS4WndKSzVyPUG4Mlc6ODFizszN	MUfTRW5ITVJ?
D-502MG	NV[yfHp3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mkf2TWM2OD1zOD64NVM6KM7:TR?=	MmHPV2FPT0WU
RO82-W-1	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2r6Z2lEPTB;MUiuPFI5QCEQvF2=	MlrCV2FPT0WU
HuO9	NIPk[ZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Moe3TWM2OD1zOT6xN\|c6KM7:TR?=	NUnrbnNOW0GQR1XS
ETK-1	MnHHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mnm2TWM2OD1zOT6xPFI4KM7:TR?=	MoPPV2FPT0WU
SNU-387	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mmf6TWM2OD1zOT6xPFg6KM7:TR?=	NHG1WVhUSU6JRWK=
SW1573	NXn3eXpMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NY\qfnVVUUN3ME2xPU4yQTZ7IN88US=>	M4XzPXNCVkeHUh?=
NTERA-S-cl-D1	NYDheXNbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUKze3VOUUN3ME2xPU4zODB5IN88US=>	M{i0VXNCVkeHUh?=
SF126	M3W0Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYPSWZNTUUN3ME2xPU4{PTB{IN88US=>	MkXiV2FPT0WU
Calu-3	M4XxR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVXrTJpjUUN3ME2xPU41OjN5IN88US=>	MUjTRW5ITVJ?
NCI-H1048	Mk\oS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUTJR\|UxRTJyLkOyOlYh\|ryP	Mn;GV2FPT0WU
NCI-H226	M3LMemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NX\vUHh[UUN3ME2yNE41Ozl7IN88US=>	NYO2TGR7W0GQR1XS
FTC-133	M33hZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUHJR\|UxRTJyLkS3NFMh\|ryP	MkLRV2FPT0WU
SF539	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGHvW4ZKSzVyPUKwMlUyPzJizszN	MWrTRW5ITVJ?
TE-6	NEK5N45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MoP4TWM2OD1{MD64NFY4KM7:TR?=	NHP3XGJUSU6JRWK=
UMC-11	MmfpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUjJR\|UxRTJyLkmxOlQh\|ryP	MYrTRW5ITVJ?
Becker	NIjoSIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWi5eJNVUUN3ME2yNU4yOTF6IN88US=>	NYDN[3I{W0GQR1XS
KP-4	NHXMZWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2S2emlEPTB;MkGuNVE6PiEQvF2=	MYjTRW5ITVJ?
ChaGo-K-1	NFuyRmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MoTyTWM2OD1{MT6zOlI4KM7:TR?=	MnvPV2FPT0WU
CFPAC-1	NF\jSnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHr6[4JKSzVyPUKxMlM5PThizszN	MlT1V2FPT0WU
A498	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFr4VXRKSzVyPUKxMlU{OTJizszN	MnOzV2FPT0WU
NCI-H1755	NIrFe2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVjJR\|UxRTJzLk[3OFEh\|ryP	Mkf5V2FPT0WU
TI-73	NGDFSZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFHwZ4JKSzVyPUKyMlMzQCEQvF2=	MkKwV2FPT0WU
NCI-H441	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUfJR\|UxRTJ{LkW2PFkh\|ryP	NWrpRlAyW0GQR1XS
CaR-1	M3XjTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVjJR\|UxRTJ\|LkCyNVMh\|ryP	NWXHbWY5W0GQR1XS
HCC1806	NF24d2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHHCW3BKSzVyPUKzMlA2QDNizszN	MUnTRW5ITVJ?
SNU-449	NV7yVGZyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXnuOop3UUN3ME2yN{4{OjlizszN	NUTNOXVYW0GQR1XS
EKVX	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{OxfmlEPTB;MkOuN\|kxQSEQvF2=	NUnKVWM5W0GQR1XS
DMS-114	MkjHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4XXfGlEPTB;MkOuOVc3PSEQvF2=	MnjZV2FPT0WU
A704	M{f3emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4jxcWlEPTB;MkOuOlExOyEQvF2=	NHHFfXdUSU6JRWK=
LC-2-ad	NGP0NVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXHJR\|UxRTJ\|Lk[xOFch\|ryP	Mmf1V2FPT0WU
VM-CUB-1	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2nkb2lEPTB;MkOuO\|M1OSEQvF2=	M4rLdHNCVkeHUh?=
PC-3	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NX62XJhoUUN3ME2yOE4xPTJ4IN88US=>	MnX3V2FPT0WU
HEL	MlfqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mk\6TWM2OD1{ND6wPFY2KM7:TR?=	MUnTRW5ITVJ?
ABC-1	NXv2eJVtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEPEflhKSzVyPUK0MlI4OjlizszN	MljQV2FPT0WU
COLO-680N	NVnTeW0yT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWD5c21TUUN3ME2yOE41PzZ2IN88US=>	NFPp[opUSU6JRWK=
MZ1-PC	NV;i[G46T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWnMUGRUUUN3ME2yOE43QDdizszN	MWDTRW5ITVJ?
NCI-H69	NEHMWodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHLqVXlKSzVyPUK0Mlc{PTRizszN	NFjyTYlUSU6JRWK=
TE-1	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUnJR\|UxRTJ3LkC0PVkh\|ryP	NVPEU3o6W0GQR1XS
EW-3	M3;wNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1fWT2lEPTB;MkWuNVE{KM7:TR?=	NXjKbZUyW0GQR1XS
PANC-08-13	NED4XWRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYPJR\|UxRTJ3LkixNFMh\|ryP	NYfSXWFXW0GQR1XS
NMC-G1	NVHBeHlJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWD6dVh1UUN3ME2yOk4xODh6IN88US=>	M1PvZXNCVkeHUh?=
BT-20	NEP0TJJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Ml3BTWM2OD1{Nj60OVQ{KM7:TR?=	M{PrRXNCVkeHUh?=
TGBC24TKB	M3TFWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NV\Sb4t{UUN3ME2yOk44OzNzIN88US=>	NUjoPIEzW0GQR1XS
TE-11	M4mwcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFLMVnZKSzVyPUK2Mlk5QTVizszN	MmjjV2FPT0WU
ESS-1	M2jLUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGe4RWRKSzVyPUK3MlMzOTZizszN	NFuwcopUSU6JRWK=
JVM-3	NHnM[WVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXnuPIQ2UUN3ME2yO{43PDd3IN88US=>	NUm2eWdWW0GQR1XS
C3A	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1rOTmlEPTB;MkeuPFQ6PiEQvF2=	MXXTRW5ITVJ?
MDA-MB-157	MlzNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUP0bWo1UUN3ME2yO{45PzV\|IN88US=>	MUTTRW5ITVJ?
KLE	MknGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3j4VGlEPTB;MkiuNVA2QCEQvF2=	MmnRV2FPT0WU
ES1	MkX0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVTJR\|UxRTJ6LkG4N\|gh\|ryP	MlvFV2FPT0WU
CAL-120	Mn3xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEL2fWpKSzVyPUK4MlM6QTlizszN	NVXJflN7W0GQR1XS
NCI-N87	Mm\ES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlniTWM2OD1{OD61NVA2KM7:TR?=	NV:1[HM6W0GQR1XS
RPMI-8226	NIHyblZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MX;JR\|UxRTJ7LkG4OFMh\|ryP	NXPwSFJYW0GQR1XS
COR-L88	NXGwXINST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYfJR\|UxRTJ7LkK0NVkh\|ryP	M4XiNHNCVkeHUh?=
UACC-893	NIDYfI9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFfYOolKSzVyPUK5MlMyOzdizszN	M1zxUHNCVkeHUh?=
C8166	M3nIRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVPKTJM5UUN3ME2yPU46QTl4IN88US=>	M1;zRnNCVkeHUh?=
J82	Mnm1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGjtbHZKSzVyPUOwMlgyPDdizszN	NVzDb2w1W0GQR1XS
PFSK-1	M2DNZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHrCT\|RKSzVyPUOxMlA3PTlizszN	M{DOO3NCVkeHUh?=
COLO-684	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2fvcWlEPTB;M{GuOFM4PCEQvF2=	NXTJNY5RW0GQR1XS
CAL-72	NX\pd2dyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlHuTWM2OD1\|MT61O\|I6KM7:TR?=	NHvIWldUSU6JRWK=
SNB75	Mn7OS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NH\CXVlKSzVyPUOxMlg6PyEQvF2=	MVjTRW5ITVJ?
MDA-MB-415	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFTkfIFKSzVyPUOxMlk4PjJizszN	MXrTRW5ITVJ?
SiHa	NGDscnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlrJTWM2OD1\|Mj60O\|EyKM7:TR?=	Mmj6V2FPT0WU
NCI-H1648	MmrkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlHITWM2OD1\|Mj65N\|Q2KM7:TR?=	MmTVV2FPT0WU
EFO-21	M{HrT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUfJR\|UxRTN\|LkCwOUDPxE1?	M2LKe3NCVkeHUh?=
HCC38	MmPuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWSxdVZkUUN3ME2zN{4{QDRzIN88US=>	MkTvV2FPT0WU
IA-LM	NWLufYVjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXvJR\|UxRTN\|Lke4PFkh\|ryP	M2mwbXNCVkeHUh?=
CTV-1	MlX5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXTJR\|UxRTN\|Lkm3PFYh\|ryP	NVjMNYVuW0GQR1XS
NCI-H446	NInJeXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnTyTWM2OD1\|ND6yOlg6KM7:TR?=	Ml7XV2FPT0WU
IST-SL1	NH75V4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4XPO2lEPTB;M{SuO\|QxQCEQvF2=	MWrTRW5ITVJ?
EW-22	NGPCUZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXHIbml1UUN3ME2zOE44PzV7IN88US=>	MmnNV2FPT0WU
JEG-3	NIS5TpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2j3UWlEPTB;M{[uNVc3PiEQvF2=	NWr0cJkyW0GQR1XS
LU-65	NWrvT3FmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Ml;HTWM2OD1\|Nj6yPVg2KM7:TR?=	M4rnPXNCVkeHUh?=
NCI-H596	NF3GT4tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVvZSoZ5UUN3ME2zOk46PTlzIN88US=>	M3fNdnNCVkeHUh?=
KNS-81-FD	NFjyOoVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWjWNFZFUUN3ME2zO{4yPDVizszN	NHToO2JUSU6JRWK=
NCI-H1793	NHq3WoJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MoPaTWM2OD1\|Nz63NFg3KM7:TR?=	NXnhbVBFW0GQR1XS
NCI-H460	MoXyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUHtXlI6UUN3ME2zPE4xQDd\|IN88US=>	MXPTRW5ITVJ?
MPP-89	MmrrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NH;3fWNKSzVyPUO5MlU5QDZizszN	NX3VSlQ3W0GQR1XS
D-542MG	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYDJR\|UxRTN7Lki0N\|Yh\|ryP	NFm2fotUSU6JRWK=
JAR	NEfzTlhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnjWTWM2OD12MD60O\|A2KM7:TR?=	MnjVV2FPT0WU
NCI-H209	M4jOfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mo\tTWM2OD12MD62O\|ch\|ryP	NWr0WnB6W0GQR1XS
G-402	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1TpTGlEPTB;NEGuN\|k6OyEQvF2=	M3jqRXNCVkeHUh?=
IST-MES1	Ml3iS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4W4OWlEPTB;NEKuNVk{PSEQvF2=	MnfqV2FPT0WU
Daoy	M17qWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MU\JR\|UxRTR{LkW0O\|Eh\|ryP	NYLV[4F5W0GQR1XS
EW-11	M1:0Wmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Ml:yTWM2OD12Mz6xNlEyKM7:TR?=	Ml7vV2FPT0WU
Saos-2	NHHmdXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXvMN\|dnUUN3ME20N{4yPTN5IN88US=>	MoruV2FPT0WU
no-10	M2DoNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmfFTWM2OD12Mz6xO\|AzKM7:TR?=	NWj3Xm03W0GQR1XS
HCC1395	NUnHfJRTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXjwZlhUUUN3ME20N{41PjR2IN88US=>	MVLTRW5ITVJ?
HCE-4	M3zkb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXXJR\|UxRTR\|Lke2OlQh\|ryP	NYrsZlB4W0GQR1XS
EW-1	M12zdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWfnfm5SUUN3ME20N{45ODR7IN88US=>	NXjvbFdxW0GQR1XS
OCUB-M	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXj0Und5UUN3ME20OE4{PjN6IN88US=>	MkXvV2FPT0WU
IGR-1	Mn23S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3K1OmlEPTB;NESuOFEyPSEQvF2=	NX30cndVW0GQR1XS
NCI-H1838	NX7DNFdNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGPtSIVKSzVyPUS0MlQ{PDlizszN	MmXJV2FPT0WU
NCI-H2405	MlrVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlzDTWM2OD12ND61N\|Qh\|ryP	NUnBVoRZW0GQR1XS
GB-1	MmfxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUXJR\|UxRTR2Lke0OlMh\|ryP	MV;TRW5ITVJ?
MG-63	MnnrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFf2N\|lKSzVyPUS2MlA3QTZizszN	NX;XV\|RTW0GQR1XS
KP-N-YN	M2fSWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlPDTWM2OD12Nj60Olc6KM7:TR?=	M4rUdXNCVkeHUh?=
no-11	NGTKOHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{CxPWlEPTB;NEeuNFI1PCEQvF2=	M{PrcnNCVkeHUh?=
SW948	MmTyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NImxNJVKSzVyPUS3MlM{PzdizszN	MlnzV2FPT0WU
CAMA-1	NIK5VIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVvJR\|UxRTR5LkO0N\|gh\|ryP	MUnTRW5ITVJ?
HCC1187	NFHxRoVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGnybnpKSzVyPUS3MlUyKM7:TR?=	NIrzboVUSU6JRWK=
D-392MG	M3v4TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4XqWmlEPTB;NEeuOlUyPiEQvF2=	M{TxfnNCVkeHUh?=
647-V	MmG4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVnJR\|UxRTR7LkO0NVQh\|ryP	M1fNXXNCVkeHUh?=

... Click to View More Cell Line Experimental Data

In vivo

Oral dosing of CI-1040 impairs the growth of colon tumor xenografts of mouse and human with a wide dose range of 48-200 mg/kg per dose, but not of P388 leukemia. ^[1] CI-1040 inhibits the tumor xenografts from PTC cells carrying a BRAF mutation with 31.3% reduction, carrying the RET/PTC1 rearrangement with 47.5% reduction than in untreated (vehicle) mice after 3 weeks of oral administration (300 mg/kg/d). No toxic effects are observed in any mice when they are treated with CI-1040. ^[2] Transient exposure of mammary tumors to CI-1040 and UCN-01 causes tumor cell death in vivo and prolonged suppression of tumor regrowth. Combined treatment with CI-1040 (25 mg/kg) and UCN-01 (0.1-0.2 mg/kg) significantly reduces MDA-MB-231, and largely abolishs MCF7 tumor growth in implanted athymic mice, while either single treatment has no significant activity. The drug combination leads to profound tumor cell death which correlates with a reduction in the phosphorylation of ERK1/2 and the immuno-reactivity of Ki67 and of CD31. ^[5]

Protocol

Kinase Assay: ^[2]	+ Expand MEK1 Assay: MAP kinase is activated after phosphorylation by MEK; the activated MAP kinase subsequently phosphorylates myelin basic protein (MBP).Incorporation of ³²P into myelin basic protein (MBP) is assayed in the presence of glutathione S-transferase (GST) fusion proteins containing the 44-kDa MAPK (GST-MAPK) or the 45-kDa MEK (GST-MEK1). Assays are conducted in 50μL of 50 mM Tris, pH 7.4/10 mM MgCl₂ /2 mM EGTA/10 μM [γ-³²P]ATP containing 10 μg of GST-MEK1, 0.5 μg of GST-MAPK, and 40 μg of MBP. After incubation at 30°C for 15 minutes, reactions are stopped by addition of Laemmli SDS sample buffer. Phosphorylated MBP is resolved by SDS/10% PAGE. This screening effort leads to the discovery of several small-molecule inhibitors of MEK, i.e. CI-1040. Experiments assessing the order of addition shows that CI-1040 directly inhibits MEK1 with a 50% inhibitory concentration (IC50) of 17 nM, without affecting the activity of MAPK.
Cell Research: ^[1]	+ Expand Cell lines: Colon 26 carcinoma cells Concentrations: 0.1-10 μM Incubation Time: 24 hours Method: Cells are planted seeded in T-75 cm ² flasks and treated the next day for 24 hous with either DMSO or CI-1040. Single-cell suspensions are collected, and pellets are fixed in ice-cold ethanol (70%) for 30 minutes. After centrifugation of the samples, propidium iodide (50 μg/mL) and RNase (30 units/mL) are added to the pellets for 20 minutes at 37 °C. After filtration, samples are analyzed by flow cytometry. (Only for Reference)
Animal Research: ^[3]	+ Expand Animal Models: PTC cells in athymic mice Formulation: Cremophor EL–95% ethanol (50:50) and dilutes with water Dosages: 150 mg/kg Administration: Orally twice daily (Only for Reference)

References

+ Expand

Solubility (25°C)

In vitro	DMSO	96 mg/mL (200.55 mM)
	Ethanol	14 mg/mL (29.24 mM)
	Water	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 30% PEG400+0.5% Tween80+5% propylene glycol, pH 9 For best results, use promptly after mixing.	10 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download PD184352 (CI-1040) SDF

Molecular Weight	478.67
Formula	C₁₇H₁₄ClF₂IN₂O₂
CAS No.	212631-79-3
Storage	3 years -20°C powder
Storage	2 years -80°C in solvent
Synonyms	N/A

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

MEK Signaling Pathway Map

MEK Inhibitors with Unique Features

Selective MEK Inhibitor

Selumetinib (AZD6244) : MEK1-selective, IC50=14 nM.
Most Potent MEK Inhibitor

PD0325901 : MEK, IC50=0.33 nM,
FDA-approved MEK Inhibitor

Trametinib (GSK1120212) : Approved by FDA for BRAF V600E mutated metastatic melanoma.
Newest MEK Inhibitor

Binimetinib (MEK162, ARRY-162, ARRY-438162) : Potent inhibitor of MEK1/2 with IC50 of 12 nM.

Related MEK Products

Cobimetinib (GDC-0973, RG7420) ^New

Cobimetinib (GDC-0973, RG7420) is a potent and highly selective MEK1 inhibitor with IC50 of 4.2 nM, showing more than 100-fold selectively for MEK1 over MEK2 and showed no significant inhibition when tested against a panel of more than 100 of serine-threonine and tyrosine kinases. Phase 3.
BI-847325 ^New

BI-847325 is an orally bioavailable, and selective dual MEK/Aurora kinase inhibitor with IC50 of 3 nM, 25 nM, 15 nM, 25 nM, and 4 nM for Xenopus laevis Aurora B, human Aurora A and Aurora C, as well as human MEK1 and MEK2, respectively. Phase 1.
GDC-0623 ^New

GDC-0623 is a potent and ATP-uncompetitive MEK1 inhibitor with K_i of 0.13 nM. Phase 1.
Trametinib (GSK1120212)

Trametinib (GSK1120212) is a highly specific and potent MEK1/2 inhibitor with IC50 of 0.92 nM/1.8 nM in cell-free assays, no inhibition of the kinase activities of c-Raf, B-Raf, ERK1/2.

Features:More potent than PD0325901 or AZD6244.
PD0325901

PD0325901 is a selective and non ATP-competitive MEK inhibitor with IC50 of 0.33 nM in cell-free assays, roughly 500-fold more potent than CI-1040 on phosphorylation of ERK1 and ERK2. Phase 2.
Selumetinib (AZD6244)

Selumetinib (AZD6244) is a potent, highly selective MEK inhibitor with IC50 of 14 nM for MEK1 and Kd value of 530 nM for MEK2. It also inhibits ERK1/2 phosphorylation with IC50 of 10 nM, no inhibition to p38α, MKK6, EGFR, ErbB2, ERK2, B-Raf, etc. Phase 3.

Features:First MEK inhibitor being tested in Phase II clinical trials.
U0126-EtOH

U0126-EtOH is a highly selective inhibitor of MEK1/2 with IC50 of 0.07 μM/0.06 μM in cell-free assays, 100-fold higher affinity for ΔN3-S218E/S222D MEK than PD98059.

Features:A chemically synthesized and highly selective inhibitor of both MEK1 and MEK2.
PD98059

PD98059 is a non-ATP competitive MEK inhibitor with IC50 of 2 μM in a cell-free assay, specifically inhibits MEK-1-mediated activation of MAPK; does not directly inhibit ERK1 or ERK2.

Features:Does not inhibit c-Raf phosphorylated MEK1.
Binimetinib (MEK162, ARRY-162, ARRY-438162)

Binimetinib (MEK162, ARRY-162, ARRY-438162) is a potent inhibitor of MEK1/2 with IC50 of 12 nM in a cell-free assay. Phase 3.
Refametinib (RDEA119, Bay 86-9766)

Refametinib (RDEA119, Bay 86-9766) is a potent, ATP non-competitive and highly selective inhibitor of MEK1 and MEK2 with IC50 of 19 nM and 47 nM, respectively.

Choose Your Country or Region

By Signaling Pathways

By product type

PD184352 (CI-1040)

Cited by 62 Publications

Purity & Quality Control

Choose Selective MEK Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download PD184352 (CI-1040) SDF

Bio Calculators

Molarity Calculator

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

Dilution Calculator

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Tech Support

MEK Signaling Pathway Map

MEK Inhibitors with Unique Features

Related MEK Products

Choose Your Country or Region

By Signaling Pathways

By product type

PD184352 (CI-1040)

Cited by 62 Publications

Purity & Quality Control

Choose Selective MEK Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download PD184352 (CI-1040) SDF

Bio Calculators

Molarity Calculator

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

Dilution Calculator

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Tech Support

MEK Signaling Pathway Map

MEK Inhibitors with Unique Features

Related MEK Products

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)